What the Due Diligence “MRI, X-Ray, and CAT Scans” Reveal
May 28, 2025
When founders imagine selling their company, they often see themselves riding off into the sunset with piles of cash. But in M&A, sunsets only come after interrogation-level diagnostics—and many don’t survive the exam. And, often when a deal does get done, it’s usually subject to a lower price or earnout, usually because the closer the buyer looked at the company, the more they saw.
And what they saw caused consternation.
In fact, more M&A deals fall apart during due diligence than during negotiation. Not because buyers lose interest, but because the closer they look, the less they like what they see. The issue isn’t always fraud or failure—it’s unreadiness, misalignment, and systemic dysfunction.
This is where the medical metaphors come in: think of due diligence as a full-body diagnostic triad—X-rays for structural health, MRIs for soft-tissue integrity (leadership, systems, culture), and CAT scans to probe the mental clarity and strategic alignment of the leadership team.
The process is intense, invasive, and illuminating. And it often reveals that the business is far more fragile than the pitch suggested.
Due Diligence Is Not a Meeting—It’s a Clinical Evaluation
Let’s strip away the niceties. Due diligence isn’t a coffee chat or a PowerPoint parade. It’s a dissection.
- X-rays reveal the skeletal structure of the business: financials, legal entities, customer contracts, and capital structure.
- MRIs delve into soft tissues: culture, leadership depth, operational scalability, and organizational processes.
- CAT scans look deeper—probing the minds and motives of the founders and executive team. What do they really believe? Do they know where they’re going? Are their strategies coherent—or just well-rehearsed sound bites?
This final scan—the CAT scan of leadership’s thinking—is often the most difficult and devastating. It exposes misalignment, ego, and intellectual fragility. And when buyers detect that, they back away—fast.
The CAT Scan: When Strategic Misalignment Becomes a Deal Killer
Buyers aren’t just acquiring a product—they’re acquiring a vision. And in many cases, they discover that the founders’ vision is either:
- Unclear: They haven’t articulated a cohesive strategic path forward.
- Unrealistic: The leadership believes in growth without infrastructure or resources.
- Misaligned: The company’s internal strategy contradicts the buyer’s integration plan or market thesis.
- Unshared: Founders disagree among themselves—or worse, pretend to agree.
This misalignment becomes painfully evident when buyers start asking second-order questions:
- “How do you plan to scale your customer acquisition without increasing CAC?”
- “Why haven’t you diversified your revenue channels?”
- “What’s your team’s succession plan if you step away?”
- “How will your platform integrate with ours within 12 months?”
Often, the answers are vague, inconsistent, or conflict with each other. Buyers read this as cognitive noise—a sign that there’s no unifying strategy or leadership maturity. And that’s when they walk.
The Expanded Anatomy of a Failed Deal: 15 Critical Findings That Derail Transactions
To survive due diligence, a company must pass all three scans. Here are the 15 most common red flags that surface—and stop deals cold:
1. No Coherent Business Plan
Without a clear, data-informed roadmap, buyers see a business running on instinct rather than insight.
2. Lack of Recurring or Predictable Revenue
Buyers want dependable, repeatable income—not one-off wins or project-based volatility.
3. Over-Reliance on Founders
If the founder is irreplaceable, the business is unsellable. Buyers need transferable value, not personality cults.
4. Weak Financial Controls
Sloppy accounting, poor recordkeeping, and unaudited statements create uncertainty. No one buys what they can’t verify.
5. Unscalable Infrastructure
Manual processes, tribal knowledge, and patchwork systems scare buyers who want growth without chaos.
6. Customer Concentration
A handful of customers generating most of the revenue makes the business brittle and risky.
7. Thin or Inexperienced Management Bench
If key executives lack experience or independence, the acquirer questions operational resilience.
8. Legal and Compliance Liabilities
Pending lawsuits, outdated contracts, regulatory exposure, or questionable IP ownership create friction and fear.
9. Inconsistent Performance Trends
Revenue and margin volatility—especially without clear explanations—create valuation doubts.
10. Strategic Misalignment with Buyer
If leadership’s goals, risk appetite, or go-to-market approach clashes with the buyer’s, integration becomes untenable.
11. Toxic or Fragile Culture
An unhealthy internal culture, high turnover, or disengaged employees signal long-term pain post-close.
12. Outdated Technology Stack
Legacy platforms, duct-taped systems, or cybersecurity vulnerabilities threaten future scalability.
13. Disorganized Diligence Response
Slow, chaotic, or incomplete responses to diligence requests signal lack of discipline—and potential hidden liabilities.
14. Opaque Cap Table
Complicated ownership structures, unresolved option grants, or misaligned investor rights complicate deal mechanics.
15. No Integration or Transition Plan
If the seller can’t explain what happens after the ink dries, the buyer loses confidence in a smooth handoff.
What the Scans Really Show: Most Companies Aren’t Built to Be Acquired
The truth is that many founders build businesses for growth, not for transfer. But buyers aren’t looking for messy potential—they’re looking for clean, scalable, integrable assets.
A company may be profitable and growing, yet still fail the X-ray (bad financial hygiene), the MRI (weak leadership or culture), or the CAT scan (no clear strategy or intellectual coherence). Passing due diligence isn’t just about survival—it’s about proof of maturity.
And in a post-LOI world, that proof must be airtight.
What Sellers Must Do: Diagnose Before You’re Diagnosed
If there’s a lesson in all this, it’s that preparation beats persuasion.
Founders who hope to exit in the next 1–3 years should subject their businesses to preemptive diagnostic imaging:
- Hire third parties to do mock due diligence.
- Conduct readiness audits on financials, tech stack, and HR policies.
- Pressure test your strategic plan—with internal dissent and external challenge.
- Align the leadership team through scenario planning and integration readiness discussions.
- Clean your cap table and document everything.
Think of it as a pre-sale physical. Find the issues before a buyer does—and fix them before they cost you the deal.
Final Thought: The Best Companies Welcome the Scan
Due diligence isn’t an enemy. It’s a diagnostic truth-teller. It reveals whether your company is built to stand on its own—or whether its strengths are surface-level and brittle.
The best companies don’t fear the X-ray, the MRI, or the CAT scan. They invite it.
Because when the scans come back clean, the deal gets done.
Paul Fioravanti, MBA, MPA, CTP, is the CEO & Managing Partner of QORVAL Partners, LLC, a FL-based advisory firm (founded 1996 by Jim Malone, (1942-2021) six-time Fortune 100/500 CEO) Qorval is a US-based growth and exit advisory, turnaround, restructuring, business optimization and interim management firm. Fioravanti is a proven advisor and CEO with experience in more than 90 situations in more than 40 industries. He earned his MBA and MPA from The University of Rhode Island and completed advanced post-master’s research in finance and marketing at Bryant University. He is a Certified Turnaround Professional and member of the Turnaround Management Association, the Private Directors Association, Association for Corporate Growth (ACG), Association of Merger & Acquisition Advisors (AM&MA), the American Bankruptcy Institute, and IMCUSA. Copyright 2025, Qorval Partners LLC and/or Paul Fioravanti, MBA, MPA, CTP. All rights reserved. No reproduction or redistribution without permission.
239 588 0008
#qorval
#turnaround
#governance
#alignment
#management
#M&A
#mergers
#acquisitions
#divestitures
#leadership
#privateequity
Need to grow, fix or exit your business?
